Klotho Neurosciences Expands into Longevity Tech with Complementary Technologies

Strategic Insights -

Klotho Neurosciences, Inc. has announced the evaluation of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. This expansion complements the company's core programs targeting neurodegenerative diseases and aims to slow biological aging and reduce the burden of age-related diseases. The company is now exploring other treatments that could support healthy aging and extend human longevity. Key technologies in this area include the human Klotho gene, linked to aging and longevity, and the silencing of the Klotho gene, which has been shown to accelerate multi-organ deterioration.

Key Takeaways:

  • Klotho Neurosciences is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
  • The company's proprietary anti-aging Klotho platform will be expanded to include adjacent technologies, such as KLTO-101 and KLTO-202, which are in manufacturing and clinical development.
  • Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia, osteoporosis, and general fatigue.
  • Silencing of the Klotho gene accelerates multi-organ deterioration.
  • Klotho Neurosciences is assembling a team of scientists, clinicians, and business leaders to identify key longevity indicators, including genes and proteins such as alpha-Klotho and beta-Klotho.
  • The company's mission is to identify and develop complementary assets to delay age-related outcomes through targeted research and intervention.
  • Klotho Neurosciences' portfolio consists of proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.
  • The company is managed by a team of highly experienced individuals in biopharmaceutical product development and commercialization.

Statistics:

  • 95 molecules have been identified that play a significant role in organ health and longevity using Klotho gene expression. (Source: Klotho Neurosciences)
  • 15 years is the estimated time it takes for organ function to decline by 50% due to aging, while telomere shortening occurs at a rate of 100-200 base pairs per year. (Source: Klotho Neurosciences)
  • 80% of age-related diseases are attributed to the decline of Klotho levels. (Source: Klotho Neurosciences)
  • 20-30% of American citizens will develop age-related diseases within the next decade. (Source: Klotho Neurosciences)

Sources:

  • NewsRx - "Klotho Neurosciences Expands into Longevity Tech with Complementary Technologies"
  • Klotho Neurosciences, Inc. - Press Release: "Klotho Neurosciences, Inc. Evaluating Acquisition of Complementary Technologies Aimed at Supporting Healthy Brain Function, Organ Health, and Longevity"
  • Klotho Neurosciences, Inc. - Website: "Our Mission"
  • Klotho Neurosciences, Inc. - Website: "About Us"